within Pharmacolibrary.Drugs.ATC.A;

model A10BD10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.063,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BD10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Combination of metformin, a biguanide antihyperglycemic agent, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Used for the treatment of type 2 diabetes mellitus to improve glycemic control, as an adjunct to diet and exercise. Approved for use in multiple regions.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults based on published data for individual components; no direct published pharmacokinetics of combination found.</p><h4>References</h4><ol><li><p>Patel, CG, et al., &amp; Boulton, DW (2011). Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. <i>Diabetes, obesity &amp; metabolism</i> 13(7) 604–614. DOI:<a href=&quot;https://doi.org/10.1111/j.1463-1326.2011.01381.x&quot;>10.1111/j.1463-1326.2011.01381.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21332626/&quot;>https://pubmed.ncbi.nlm.nih.gov/21332626</a></p></li><li><p>Boulton, DW, et al., &amp; LaCreta, FP (2011). Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. <i>Clinical drug investigation</i> 31(9) 619–630. DOI:<a href=&quot;https://doi.org/10.2165/11590290-000000000-00000&quot;>10.2165/11590290-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21819160/&quot;>https://pubmed.ncbi.nlm.nih.gov/21819160</a></p></li><li><p>Upreti, VV, et al., &amp; Lacreta, FP (2013). Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects. <i>Clinical drug investigation</i> 33(5) 365–374. DOI:<a href=&quot;https://doi.org/10.1007/s40261-013-0075-z&quot;>10.1007/s40261-013-0075-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23549864/&quot;>https://pubmed.ncbi.nlm.nih.gov/23549864</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BD10;
